Biopharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing Plant
- Client
- AGC Corporation
- Location
- AGC Yokohama Technical Center, Tsurumi-ku, Yokohama, Kanagawa, Japan
- Scope of Work
- Engineering, Procurement, Construction and Validation (E.P.C.V)
Contributing to Enhancing the Domestic Development and Manufacturing Capacity of Biopharmaceuticals
This project is the engineering, procurement and construction (EPC) of manufacturing facilities to expand the biopharmaceutical development and manufacturing capacity of AGC Corporation (AGC), a Contract Development & Manufacturing Organization (CDMO), within their Yokohama Technical Center.
The project has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its ‘Development of biopharmaceutical manufacturing sites to strengthen vaccine production’ program. The facilities will be used for biopharmaceutical manufacturing during regular times and can be switched to vaccine manufacturing during pandemics, enabling dual-use functionality.
Cutting-edge facilities for the development and manufacturing of mRNA pharmaceuticals, gene therapies and cell therapies will also be introduced.
Through the execution of this project, Chiyoda will contribute to enhancing the domestic development and manufacturing capacity of biopharmaceuticals, reducing dependence on overseas sources.